纳武利尤单抗联合伊匹木单抗治疗经索拉非尼治疗的晚期肝细胞癌:CheckMate 040随机临床试验
CheckMate 040是一项多中心、开放标签、多队列1/2期研究,纳入148例经索拉非尼治疗的晚期肝细胞癌患者,随机分配至三种纳武利尤单抗联合伊匹木单抗方案。主要终点为安全性、耐受性和客观缓解率。结果显示三个臂的客观缓解率分别为32%、27%和29%,缓解持续时间持久,安全性可控。
要点
- A臂客观缓解率32%,B臂27%,C臂29%。
- A臂缓解持续时间未达到,B臂15.2个月,C臂21.7个月。
- A臂方案基于本研究获美国加速批准。
核心结论
- 纳武利尤单抗联合伊匹木单抗在经索拉非尼治疗的晚期肝细胞癌患者中具有可控的安全性和有前景的客观缓解率,且缓解持久。
研究设计与样本
- CheckMate 040为多中心、开放标签、多队列1/2期研究,在亚洲、欧洲和北美10个国家/地区的31个中心招募患者。
- 共148例经索拉非尼治疗的晚期肝细胞癌患者随机分配(A臂50例,B臂和C臂各49例),中位随访30.7个月,数据截止2019年1月。
主要发现
- 研究者评估的客观缓解率:A臂32%(95% CI,20%-47%),B臂27%(95% CI,15%-41%),C臂29%(95% CI,17%-43%)。
- 中位缓解持续时间:A臂未达到(范围8.3-33.7+个月),B臂15.2个月(范围4.2-29.9+个月),C臂21.7个月(范围2.8-32.7+个月)。
- 任何级别治疗相关不良事件发生率:A臂94%(46/49),B臂71%(35/49),C臂79%(38/48);A臂发生1例治疗相关死亡(5级肺炎)。
关键数值与推荐
- A臂方案:纳武利尤单抗1 mg/kg联合伊匹木单抗3 mg/kg,每3周一次,共4剂,随后纳武利尤单抗240 mg每2周一次。
- B臂方案:纳武利尤单抗3 mg/kg联合伊匹木单抗1 mg/kg,每3周一次,共4剂,随后纳武利尤单抗240 mg每2周一次。
- C臂方案:纳武利尤单抗3 mg/kg每2周一次联合伊匹木单抗1 mg/kg每6周一次。
临床怎么用
- 对于经索拉非尼治疗的晚期肝细胞癌患者,可考虑使用纳武利尤单抗联合伊匹木单抗方案。
- A臂方案(4剂纳武利尤单抗1 mg/kg联合伊匹木单抗3 mg/kg每3周一次,随后纳武利尤单抗240 mg每2周一次)基于本研究获美国加速批准。
- 治疗期间需密切监测治疗相关不良事件,包括肺炎等严重不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Most patients with hepatocellular carcinoma (HCC) are diagnosed with advanced disease not eligible for potentially curative therapies; therefore, new treatment options are needed. Combining nivolumab with ipilimumab may improve clinical outcomes compared with nivolumab monotherapy. OBJECTIVE: To assess efficacy and safety of nivolumab plus ipilimumab in patients with advanced HCC who were previously treated with sorafenib. DESIGN, SETTING, AND PARTICIPANTS: CheckMate 040 is a multicenter, open-label, multicohort, phase 1/2 study. In the nivolumab plus ipilimumab cohort, patients were randomized between January 4 and September 26, 2016. Treatment group information was blinded after randomization. Median follow-up was 30.7 months. Data cutoff for this analysis was January 2019. Patients were recruited at 31 centers in 10 countries/territories in Asia, Europe, and North America. Eligible patients had advanced HCC (with/without hepatitis B or C) previously treated with sorafenib. A total of 148 patients were randomized (50 to arm A and 49 each to arms B and C). INTERVENTIONS: Patients were randomized 1:1:1 to either nivolumab 1 mg/kg plus ipilimumab 3 mg/kg, administered every 3 weeks (4 doses), followed by nivolumab 240 mg every 2 weeks (arm A); nivolumab 3 mg/kg plus ipilimumab 1 mg/kg, administered every 3 weeks (4 doses), followed by nivolumab 240 mg every 2 weeks (arm B); or nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (arm C). MAIN OUTCOMES AND MEASURES: Coprimary end points were safety, tolerability, and objective response rate. Duration of response was also measured (investigator assessed with the Response Evaluation Criteria in Solid Tumors v1.1). RESULTS: Of 148 total participants, 120 were male (81%). Median (IQR) age was 60 (52.5-66.5). At data cutoff (January 2019), the median follow-up was 30.7 months (IQR, 29.9-34.7). Investigator-assessed objective response rate was 32% (95% CI, 20%-47%) in arm A, 27% (95% CI, 15%-41%) in arm B, and 29% (95% CI, 17%-43%) in arm C. Median (range) duration of response was not reached (8.3-33.7+) in arm A and was 15.2 months (4.2-29.9+) in arm B and 21.7 months (2.8-32.7+) in arm C. Any-grade treatment-related adverse events were reported in 46 of 49 patients (94%) in arm A, 35 of 49 patients (71%) in arm B, and 38 of 48 patients (79%) in arm C; there was 1 treatment-related death (arm A; grade 5 pneumonitis). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, nivolumab plus ipilimumab had manageable safety, promising objective response rate, and durable responses. The arm A regimen (4 doses nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks then nivolumab 240 mg every 2 weeks) received accelerated approval in the US based on the results of this study. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01658878.
引用
- Yau T, Kang YK, Kim TY, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol. 2020. PMID: 33001135. doi:10.1001/jamaoncol.2020.4564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。